On the stock market since 2006, it operates in the world of money and finance. It has 235 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 17% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 3 years, sales grew about 16% a year on average.
Sales run at $84.8M a year. A small number, but proof the product has real buyers.
A loss of $17.0M against $84.8M in annual sales. And on top of that, sales fell from the year before.
The price action doesn’t yet back an upward turn.
On our five-subject report card, HBMD sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: HBMD is a high-risk stock — not yet profitable, and its future rides on its product catching on.